Streetbeat News

Price Targets

DFIN

Needham analyst Kyle Peterson has reiterated a Buy rating on Donnelley Financial Solutions, Inc. (DFIN), raising the price target to $65 from $56. Peterson applauds DFIN's transition from print to software, which has boosted margins and efficiency. Despite margin compression due to weaker capital markets activity, Peterson expects margins to improve steadily in FY24 and beyond. The analyst also raised FY23 and FY24 revenue estimates for DFIN.

Portfolio Pulse from Nabaparna Bhattacharya

September 29, 2023 | 7:01 pm

GPCR

Jefferies analyst Chris Howerton maintains a Buy rating on Structure Therapeutics (NASDAQ:GPCR) and raises the price target from $50 to $79.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 6:29 pm

KLAC

A significant bearish stance has been taken on KLA (NASDAQ:KLAC) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is 70% bearish and 30% bullish. The whales have been targeting a price range from $485.0 to $510.0 for KLA over the last 3 months. Wolfe Research has downgraded its action to Outperform with a price target of $600.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:18 pm

ALGM

In the last quarter, Allegro Microsystems (NASDAQ:ALGM) received 6 analyst ratings, with 3 being bullish, 2 somewhat bullish, and 1 indifferent. The company's average 12-month price target is $52.0, an increase of 2.62% from the previous average of $50.67.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:00 pm

ICFI

ICF International (NASDAQ:ICFI) has received positive analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish ratings. The company's average 12-month price target has increased by 4.04% from $136.00 to $141.5.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 6:00 pm

ABBV

Raymond James has initiated coverage on AbbVie Inc (ABBV) with an Outperform rating and a price target of $177. The analysts believe that ABBV is showing resilience and adaptability, successfully navigating the U.S. loss of exclusivity for Humira and surpassing initial projections. They anticipate a resurgence of mid- to high-single-digit growth in both the top and bottom lines by 2025. ABBV's strategic outlook is intertwined with proactive mergers and acquisitions, and the market can expect increased M&A activity over the next 6-18 months.

Portfolio Pulse from Vandana Singh

September 29, 2023 | 5:37 pm

GNS

Zacks Small-Cap Research has set a valuation of $5 for Genius Group. The company's stock is expected to be impacted by this valuation.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 5:12 pm

TMCI

UBS has initiated coverage on Treace Medical Concepts with a Buy rating and a price target of $24. This has led to an increase in the trading of Treace Medical Concepts shares.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 4:26 pm

FUSN

NVS

Oppenheimer has initiated coverage on Fusion Pharmaceuticals Inc (FUSN) with an Outperform rating and a price target of $13. The firm cites Fusion's pipeline as among the best in the targeted radionuclide therapies (TRTs) space, with three candidates currently in clinical development. The analysts also highlight Fusion's potential to compete directly against beta-emitter treatments for patients, which could provide over 2x upside to Oppenheimer's current valuation. The interim Phase 2 data from FPI-2265 in mCRPC patients, anticipated 1Q24, is expected to have a potential impact.

Portfolio Pulse from Vandana Singh

September 29, 2023 | 4:21 pm

PNC

RBC Capital analyst Gerard Cassidy has reiterated an 'Outperform' rating on PNC Financial Services Group (NYSE:PNC) and maintained a price target of $140.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 4:16 pm